Advancing ALS Drug Discovery with iPSC-Derived Neurons & Glia
- Senior Business Development provides a range of human iPSC-derived neurons and glia from healthy and disease lines for use in drug discovery applications
- Differentiating ALS patient lines harbouring mutations in disease-relevant genes (i.e. C9ORF72, SOD1, TDP-43) into various cells of the CNS and generating isogenic controls
- Disease modeling with mono-, co-, and triculture systems to advance personalized medicine for ALS and other neurodegenerative diseases